OBJECTIVE: Metabolomics is a new "omics" platform aimed at high-throughput identification, quantification and characterization of small-molecule metabolites. The metabolomics approach has been successfully applied to the classification different physiological states and identification of perturbed biochemical pathways. The purpose of the current investigation is the application of metabolomics to explore biological mechanisms which may lead to the onset of metabolic syndrome in adulthood. METHODS: We evaluated differences in metabolites in the urine collected within 12 h from 23 infants with IUGR (IntraUterine Growth Restriction), or LGA (Large for Gestational Age), compared to control infants (10 patients defined AGA: Appropriate for Gestational Age). Urinary metabolites were quantified by GC-MS and used to highlight similarities between the two metabolic diseases and identify metabolic markers for their predisposition. Quantified metabolites were analyzed using a multivariate statistics coupled with receiver operator characteristic curve (ROC) analysis of identified biomarkers. RESULTS: Urinary myo-inositol was the most important discriminant between LGA + IUGR and control infants, and displayed an area under the ROC curve = 1. CONCLUSION: We postulate that the increase in plasma and consequently urinary inositol may constitute a marker of altered glucose metabolism during fetal development in both IUGR and LGA newborns.
OBJECTIVE: Metabolomics is a new "omics" platform aimed at high-throughput identification, quantification and characterization of small-molecule metabolites. The metabolomics approach has been successfully applied to the classification different physiological states and identification of perturbed biochemical pathways. The purpose of the current investigation is the application of metabolomics to explore biological mechanisms which may lead to the onset of metabolic syndrome in adulthood. METHODS: We evaluated differences in metabolites in the urine collected within 12 h from 23 infants with IUGR (IntraUterine Growth Restriction), or LGA (Large for Gestational Age), compared to control infants (10 patients defined AGA: Appropriate for Gestational Age). Urinary metabolites were quantified by GC-MS and used to highlight similarities between the two metabolic diseases and identify metabolic markers for their predisposition. Quantified metabolites were analyzed using a multivariate statistics coupled with receiver operator characteristic curve (ROC) analysis of identified biomarkers. RESULTS: Urinary myo-inositol was the most important discriminant between LGA + IUGR and control infants, and displayed an area under the ROC curve = 1. CONCLUSION: We postulate that the increase in plasma and consequently urinary inositol may constitute a marker of altered glucose metabolism during fetal development in both IUGR and LGA newborns.
Authors: Kelly Mercier; Susan McRitchie; Wimal Pathmasiri; Andrew Novokhatny; Rajesh Koralkar; David Askenazi; Patrick D Brophy; Susan Sumner Journal: Pediatr Nephrol Date: 2016-07-19 Impact factor: 3.714
Authors: Maxim D Seferovic; Danielle M Goodspeed; Derrick M Chu; Laura A Krannich; Pablo J Gonzalez-Rodriguez; James E Cox; Kjersti M Aagaard Journal: FASEB J Date: 2015-03-10 Impact factor: 5.191
Authors: Philip G Murray; Imogen Butcher; Warwick B Dunn; Adam Stevens; Reena Perchard; Daniel Hanson; Andrew Whatmore; Melissa Westwood; Peter E Clayton Journal: Pediatr Res Date: 2016-04-08 Impact factor: 3.756
Authors: Sarah Jane Metrustry; Ville Karhunen; Mark H Edwards; Cristina Menni; Thomas Geisendorfer; Anja Huber; Christian Reichel; Elaine M Dennison; Cyrus Cooper; Tim Spector; Marjo-Riitta Jarvelin; Ana M Valdes Journal: PLoS One Date: 2018-03-22 Impact factor: 3.240
Authors: Luc P Brion; Dale L Phelps; Robert M Ward; Tracy L Nolen; N Mikko K Hallman; Abhik Das; Daniel J Zaccaro; M Bethany Ball; Kristi L Watterberg; Ivan D Frantz; C Michael Cotten; Brenda B Poindexter; William Oh; Ralph A Lugo; Krisa P Van Meurs; T Michael O'Shea; Kristin M Zaterka-Baxter; Rosemary D Higgins Journal: J Perinatol Date: 2020-09-15 Impact factor: 2.521